Three off-white ceramic bowls in a row from smallest to largest on sage linen, with a small olive sprig
Three off-white ceramic bowls in a row from smallest to largest on sage linen, with a small olive sprig

Why does Ozempic or Zepbound start with a low starter dose?

It's a ramp, and your prescriber sets the pace

November 20, 2026 · 4 min read
Updated November 18, 2026
Text it

Checkin shares general health information from FDA labels and published studies. It isn't medical advice, so check with your prescriber about your medicine. Questions about this? Text Checkin, it's free.

The short answer: GLP-1 labels start with a low dose and step up slowly to lower the risk of stomach side effects like nausea, vomiting and diarrhea. The starter dose is for getting started; your prescriber decides when, and whether, you move up.

If your first prescription is for the lowest dose, that's by design. All four labels, for Ozempic, Wegovy, Mounjaro and Zepbound, begin low and go up in steps. Here is the reason the labels give, and who decides what comes next.

1.Why do GLP-1 doses start low?

“Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions”
What the label saysOzempic prescribing information, section 2.2

"Dosage escalation" means stepping the dose up. "Gastrointestinal adverse reactions" means stomach and gut side effects. The Wegovy label (section 2.2) and the Mounjaro and Zepbound labels (section 2.1) give the same reason.

To see why a slow start helps, it helps to know what the medicine does. Many cells in your body have GLP-1 receptors. You can picture a receptor as a lock on the cell. The Ozempic label says the medicine "selectively binds to and activates the GLP-1 receptor" (section 12.1). It fits the lock and turns it.

One result is that food leaves the stomach more slowly. The Wegovy label says it plainly: "Semaglutide delays gastric emptying" (section 12.2).

For tirzepatide (Mounjaro and Zepbound), the label describes how that changes: "The delay is largest after the first dose and this effect diminishes over time" (Zepbound section 12.2). In other words, the effect on the stomach is strongest at the very beginning.

There is also a build-up. Semaglutide has a half-life of about 1 week (Ozempic section 12.3). Half-life is the time it takes for the amount in your body to drop by half. So when the next weekly shot comes, some of the last one is still there, and the level in your body rises at first. A low starting dose keeps that rise gentle.

2.When do side effects tend to happen?

“The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation.”
What the label saysOzempic prescribing information, section 6.1

The Mounjaro label says the same, and adds that these side effects "decreased over time" (section 6.1). So does the Zepbound label (section 6.1).

3.Is the starter dose a real dose?

It's real medicine, and it has its own job. The Zepbound label says its starting dose "is for treatment initiation and is not approved as a maintenance dosage" (section 2.1). Treatment initiation means getting started. A maintenance dosage is the dose someone stays on long term.

So think of the starter dose as a ramp. It's there to let your body get used to the medicine. The first weeks aren't the test of how the medicine will go for you, and it's worth telling your prescriber what you notice either way.

4.Who decides when to step up?

Your prescriber. The labels tie the long-term dose to you, not to a calendar. The Wegovy and Zepbound labels tell prescribers to "consider treatment response and tolerability" (Wegovy section 2.2, Zepbound section 2.1). Tolerability means how well you're handling the medicine. The Ozempic and Mounjaro labels base it on blood sugar control (Ozempic section 2.2, Mounjaro section 2.1).

“Use MOUNJARO exactly as your healthcare provider tells you to.”
What the label saysMounjaro Medication Guide

5.What if a step is hard to tolerate?

Say so. The labels give prescribers options. The Wegovy label says that if a dose isn't tolerated during the step-up, the prescriber can consider delaying the next step (section 2.2). The Zepbound label says that if a maintenance dose isn't tolerated, the prescriber can "consider a lower maintenance dosage" (section 2.1).

Those are your prescriber's choices to make. They can only make them if they know how each step is going for you.

6.Why does the step-up period matter for fluids?

Vomiting and diarrhea can drain fluid from your body, and that can be hard on the kidneys. The Ozempic label tells prescribers to check kidney function in people with side effects that could cause fluid loss, "especially during dosage initiation and escalation" (section 5.6).

So during the start and the step-ups, keep sipping fluids. If vomiting or diarrhea won't stop, call your healthcare provider.

How Checkin helps in your first weeks

Checkin is a free AI companion for GLP-1s that you text. For this part of life on a GLP-1, it does three things:

  • Text “took my shot”

    It's logged, so you can see your weeks add up.

  • It checks in two days after your shot

    A quick text to see how you're feeling, timed to your shot day.

  • Ask anything

    Plain answers from the FDA label, with a picture when it helps.

Questions people ask

Why is my first dose so small?

Labels start low and step up slowly to lower the risk of stomach side effects. Your prescriber sets each step.

Should I move up if I feel fine?

That's your prescriber's decision. Tell them how you're feeling and they'll decide.

Can I stay on a lower dose?

Labels let prescribers choose the long-term dose based on response and tolerability. Ask yours.

Is it bad if I feel nothing on the starter dose?

The starter dose is meant for getting used to the medicine. Talk to your prescriber about how it's going.

Sources

  1. DailyMed: Ozempic (semaglutide) prescribing information, sections 2.2, 5.6, 6.1, 12.1 and 12.3
  2. DailyMed: Wegovy (semaglutide) prescribing information, sections 2.2 and 12.2
  3. DailyMed: Mounjaro (tirzepatide) prescribing information, sections 2.1 and 6.1, and Medication Guide
  4. DailyMed: Zepbound (tirzepatide) prescribing information, sections 2.1, 6.1 and 12.2

Published November 20, 2026. General information, not medical, legal or insurance advice. Check with your prescriber, pharmacist or plan.

The Checkin team writes these guides from FDA labels and published studies, and lists a source for every claim. Read more about Checkin, or text it free.

Related guides